Yanyan Qian1, Jupeng Yuan1, Huili Hu1, Qifeng Yang2, Jisheng Li3,Shuqian Zhang1, Baichun Jiang1, Changshun Shao1,*, and Yaoqin Gong1,*
Author Affiliations
1Key Laboratory of Experimental Teratology, Ministry of Education/Institute of Molecular Medicine and Genetics, Shandong University School of Medicine, Jinan, China.
2Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan, China.
3Department of Medical Oncology, Cancer Center, Qilu Hospital, Shandong University, Jinan, China.
Corresponding Authors:
Yaoqin Gong, Shandong University School of Medicine, Jinan, Shandong 250012, China. Phone: 86-531-8838-2115; Fax: 86-531-8838-2502; E-mail: yxg8@sdu.edu.cn; and Changshun Shao, changshun.shao@gmail.com
Cancer progression requires a permissive microenvironment that shields cancer from the host immunosurveillance. The presence of myeloid-derived suppressor cells (MDSC) is a key feature of a tumor-permissive microenvironment. Cullin 4B (CUL4B), a scaffold protein in the Cullin 4B-RING E3 ligase complex (CRL4B), represses tumor suppressors through diverse epigenetic mechanisms and is overexpressed in many malignancies. We report here that CUL4B unexpectedly functions as a negative regulator of MDSC functions in multiple tumor settings. Conditional ablation of CUL4B in the hematopoietic system, driven by Tek-Cre, resulted in significantly enhanced accumulation and activity of MDSCs. Mechanistically, we demonstrate that the aberrant abundance of MDSCs in the absence of CUL4B was mediated by the downregulation of the AKT/β-catenin pathway. Moreover, CUL4B repressed the phosphatases PP2A and PHLPP1/2 that dephosphorylate and inactivate AKT to sustain pathway activation. Importantly, the CUL4B/AKT/β-catenin axis was downregulated in MDSCs of healthy individuals and was further suppressed in tumor-bearing mice and cancer patients. Thus, our findings point to a pro- and antitumorigenic role for CUL4B in malignancy, in which its ability to impede the formation of a tumor-supportive microenvironment may be context-specific. Cancer Res; 75(23); 5070–83. ©2015 AACR.
Disclaimer: Only abstract of articles from non-members were published. This page aims to promote Chinese scientific research. There is no conflicts of interest with any journals reserved the copyright. For more please contact the author.
Copyright © 1998 - 2024 Chinese Society of Clinical Oncology(CSCO). All Rights Reserved
Contact Us
EMAIL:office@csco.org.cn
international@csco.org.cn
Phone:86(10)67726451 (Beijing)
86(25)84547290 (Nanjing)